

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
11 September 2009 (11.09.2009)

(10) International Publication Number
WO 2009/109643 A3

(51) International Patent Classification:

A61K 38/20 (2006.01) A61K 39/12 (2006.01)
C07K 14/545 (2006.01) A61P 3/10 (2006.01)

MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO,
NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG,
SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA,
UG, US, UZ, VC, VN, ZA, ZM, ZW.

(21) International Application Number:

PCT/EP2009/052639

(22) International Filing Date:

5 March 2009 (05.03.2009)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

08152336.7 5 March 2008 (05.03.2008) EP

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM,
ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ,
TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR),
OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML,
MR, NE, SN, TD, TG).

(71) Applicant (for all designated States except US): **CYTOS
BIOTECHNOLOGY AG** [CH/CH]; Wagistrasse 25,
CH-8952 Schlieren (CH).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **BACHMANN,
Martin** [CH/CH]; Goldackerweg 8, CH-8472 Seuzach
(CH). **SPOHN, Gunther** [DE/CH]; Michelstrasse 15,
CH-8049 Zürich (CH).

(74) Agent: **PETER, Stefan**; Cytos Biotechnology AG, Wag-
istrasse 25, CH-8952 Schlieren (CH).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ,
CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ,
EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR,
KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME,

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted
a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of
the earlier application (Rule 4.17(iii))
- of inventorship (Rule 4.17(iv))

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments (Rule 48.2(h))
- with sequence listing part of description (Rule 5.2(a))

(88) Date of publication of the international search report:

5 November 2009

(54) Title: USE OF INTERLEUKIN-1 CONJUGATES IN THE TREATMENT OF DIABETES

(57) Abstract: The invention provides compositions, pharmaceutical compositions and vaccines for the treatment, amelioration and / or prophylaxis of diabetes, preferably of type II diabetes. The compositions, pharmaceutical compositions and vaccines of the invention comprise a core particle and an antigen, wherein said antigen comprises an interleukin-1 (IL-I) molecule. When administered to an animal, preferably to a human, said compositions, pharmaceutical compositions, and vaccines induce efficient immune responses, in particular antibody responses, wherein typically and preferably said antibody responses are directed against IL-I. Thus, the invention provides methods of treating, ameliorating or preventing diabetes, preferably type II diabetes, by way of active immunization against IL-I.



WO 2009/109643 A3